Colestilan

Colestilan

Colestilan is a bile acid sequestrant used in the treatment of hyperphosphatemia. It is a non-absorbable, non-calcium, and non-aluminium-based phosphate binder that was developed by Mitsubishi Tanabe Pharma and is marketed under the brand name BindRen.

Pharmacology

Colestilan works by binding to dietary phosphate in the digestive tract, which reduces the amount of phosphate absorbed into the body. This mechanism of action is similar to other bile acid sequestrants, such as colestipol and cholestyramine. However, unlike these drugs, colestilan does not bind to bile acids, which reduces the risk of side effects related to fat malabsorption.

Clinical Use

Colestilan is used in the treatment of hyperphosphatemia, particularly in patients with chronic kidney disease. Hyperphosphatemia is a common complication of chronic kidney disease, and can lead to serious health problems such as bone disease and cardiovascular disease. By reducing the amount of phosphate absorbed into the body, colestilan can help to lower phosphate levels in the blood and reduce the risk of these complications.

Side Effects

The most common side effects of colestilan are gastrointestinal, including constipation, diarrhea, and abdominal pain. These side effects are generally mild and can often be managed by adjusting the dose of the drug. Rarely, colestilan can cause more serious side effects, such as bowel obstruction.

See Also

• Bile acid sequestrant
• Hyperphosphatemia
• Chronic kidney disease
• Mitsubishi Tanabe Pharma

‎

‎